Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 786 participants.
Also called NCT07347626
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 786 participants
- Registry
-
NCT07347626
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07347626. Randomized; single masking; primary purpose treatment. Start 2026-03-01 (anticipated); primary completion 2029-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis
- Acronym
- E-TWIST
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Eptifibatide (Integrilin)
- Intervention (Drug)
- Standard Medical Therapy
- Lead sponsor
- Xinqiao Hospital of Chongqing
- Collaborator
- The First Affiliated Hospital of Hainan Medical University
- Collaborator
- The First Affiliated Hospital of Nanchang University
Record details
- Record id
cardio:ct-nct07347626- Content hash
9b04295553c7be2ed6a5a4082b78327cf4bbc9e36c59c34ac1f3d9137735c842